Track your medical treatment, symptoms and their causes, and check your lung function with a single device!
Not available. CE certification pending.
IMPROVED THERAPEUTIC RESULTS
The effectiveness of your inhalation therapy depends also on you! By using the Spirocco Ultihale you can:
optimize your drug therapy
learn about the root causes
track the current status and trends of your respiratory function in the app
share information with your doctor so you can work together on the improvement of your health
No additional device is needed to measure the most important respiratory parameters!
Thanks to its built-in flow meter Spirocco Ultihale can measure PEF, FEV1, FVC.
Provides feedback on the use of the device
Press and inhale!
Press and measure!
Use the speaker to find the device in the room
Ventolin / Flixotide / Foster/ Trimbow
The Spirocco app adapts to the user's lifestyle, can be used any time and, thanks to its compact design, can even fit in a pocket.
The device logs the activation of the inhaler, records the inhalation period and the pressure drop during aspiration, and also indicates whether the product has been shaken before use.
You can track your inhalation therapy and respiratory function on daily, weekly, monthly and yearly basis. The app logs the environmental parameters (pollen, air pollution, temperature, humidity) so you can get a comprehensive picture of the causes of the changes in your condition.
The data can automatically be shared with the doctors supporting them in making better and faster clinical decisions
Easily traceable results
Consultation via video chat and messaging
Medication reminder function
Continuous monitoring of respiratory condition and symptoms
Internal questionnaire that helps to determine the level of GINA asthma control
You can simply measure the PEF value and track its changes with our device and app.
Clinical trials demonstrate that digitally supported drug therapy significantly improves the effectiveness of the treatment:
less quick-relief medications used by children
(Chan et al, 2015)
less exacerbation in adults
(Foster et al, 2015)
more properly controlled patients